Quick answer: Research peptides are synthetic amino acid chains sold for laboratory use rather than as approved medicines. Most of the well-known names, including BPC-157, TB-500, ipamorelin and epitalon, have never completed a phase III human trial and are not approved anywhere. 2026 shifted the regulatory picture: in April the FDA removed twelve peptide bulk substances from a restrictive category, and on 23 and 24 July its Pharmacy Compounding Advisory Committee recommended six of seven reviewed peptides for the 503A compounding list. None of that made any of them an approved drug or a legal supplement.
The three legal buckets
Almost every argument about peptides online comes from people conflating these categories.
- Approved drugs. Peptides with full marketing authorisation for specific indications, such as semaglutide and tirzepatide for obesity and diabetes, tesamorelin for HIV-associated lipodystrophy, and teriparatide for osteoporosis. These have dossiers, labels and pharmacovigilance.
- Compoundable bulk substances. Substances a licensed pharmacy may compound for an individual patient under prescription, governed by the 503A and 503B bulks lists. This is the category the July 2026 vote concerned.
- Research use only chemicals. Everything else. Sold for laboratory research, explicitly not for human consumption, with no requirement for pharmaceutical manufacturing standards.
The third bucket is where most consumer purchasing happens, and it is the one with the fewest protections. Our explainer on what research use only actually means unpacks the label language in detail.
What happened in 2026
The sequence matters, because it is widely misreported as an approval.
On 15 April 2026 the FDA removed twelve peptide bulk substances from Category 2 of its bulk drug substances list, the classification reserved for substances raising significant safety concerns in compounding. On 23 and 24 July 2026 the Pharmacy Compounding Advisory Committee reviewed seven peptides and voted in favour of six for the 503A bulks list: BPC-157, KPV, TB-500, MOTS-c, epitalon and semax. Emideltide was rejected. Contemporaneous reporting described several votes as close, one recorded as eight in favour, six against and one abstention, with FDA scientific staff highlighting how few human studies were available.
What that means in practice, if the FDA follows the recommendation, is that a compounding pharmacy could prepare those peptides for a named patient with a prescription. It does not create over-the-counter access, it does not validate efficacy, and it does not legalise selling them as supplements.
Running alongside this was continued enforcement pressure on compounded GLP-1 medicines after the shortage-driven exemptions ended, which reshaped the weight-loss peptide market considerably. We cover that side in our comparison of GLP-1, GLP-2 and GLP-3 peptides.
The peptide families people actually ask about
- Repair and recovery: BPC-157 and TB-500, both preclinical in terms of completed evidence, both prohibited in sport.
- Growth hormone secretagogues: ipamorelin, CJC-1295, hexarelin, sermorelin. Tesamorelin is the approved member of this family, for a narrow indication.
- Metabolic: the approved incretin drugs, plus research compounds such as MOTS-c with early-stage data.
- Cosmetic and dermatological: GHK-Cu and KPV, mainly studied topically.
- Neurological and nootropic: semax and selank, used clinically in some countries outside the United States and unapproved within it.
- Longevity: epitalon, with a thin and largely single-country literature.
- Melanocortin: melanotan II, which carries documented harms including changes in existing moles and reports of serious adverse events, and which is not the same as the approved drugs afamelanotide or bremelanotide.
How to read a peptide certificate of analysis
If you are evaluating documentation, these are the fields that carry information rather than reassurance.
- Identity by mass spectrometry. The measured molecular weight should match the theoretical weight for the stated sequence. Purity without identity is meaningless.
- Purity by HPLC, with the chromatogram attached. A percentage printed on a PDF with no trace behind it is a claim, not data.
- Peptide content versus net peptide. A vial can be 99 percent pure peptide by HPLC while a significant share of the powder mass is salts and water.
- Endotoxin and sterility. Rarely provided by research suppliers, and directly relevant to anything injectable.
- Batch and date. The lot number on the certificate should match the vial, and peptides degrade with heat and time.
Independent testing of grey-market peptides has repeatedly found underdosed, overdosed, degraded and misidentified products. That is the core practical risk, separate from any pharmacology.
Risks that do not depend on the specific molecule
Unapproved injectables share a risk profile regardless of sequence: contamination and infection from non-sterile preparation, immunogenic reactions to impurities, dosing errors from reconstitution arithmetic, unknown interactions with prescription medicines, and no adverse event monitoring system to catch problems. For competitive athletes, add the anti-doping dimension, since most of these substances sit on WADA’s prohibited list at all times.
Frequently asked questions
Are research peptides legal?
Selling them for laboratory research is generally permitted. Selling or marketing them for human use without approval is not, and they are not lawful dietary supplement ingredients.
Did the FDA approve peptides in 2026?
No. An advisory committee recommended six peptides for the 503A compounding bulks list in July 2026. Drug approval is a separate process that has not happened.
Which six peptides were recommended?
BPC-157, KPV, TB-500, MOTS-c, epitalon and semax.
Does research use only mean it is unsafe?
It means the product was not manufactured or tested for human use. Sterility, identity and purity are not guaranteed, which is a safety problem regardless of the molecule.
Can a doctor prescribe these peptides?
Clinicians can prescribe approved drugs, and compounded preparations where the substance is permitted. Rules differ by country and state, and the 503A list is the mechanism under discussion in the United States.
Are peptides banned in sport?
Most unapproved peptides fall under WADA’s prohibited list, several in the S0 non-approved substances category, which applies at all times.
This article is a regulatory and research summary for general information. It is not medical advice and is not a recommendation to obtain or use any unapproved peptide. Discuss any peptide therapy with a qualified clinician.